238 related articles for article (PubMed ID: 19222785)
1. Mast cell degranulation contributes to susceptibility to Leishmania major.
Romão PR; Da Costa Santiago H; Ramos CD; De Oliveira CF; Monteiro MC; De Queiroz Cunha F; Vieira LQ
Parasite Immunol; 2009 Mar; 31(3):140-6. PubMed ID: 19222785
[TBL] [Abstract][Full Text] [Related]
2. Mast cells augment lesion size and persistence during experimental Leishmania major infection in the mouse.
Wershil BK; Theodos CM; Galli SJ; Titus RG
J Immunol; 1994 May; 152(9):4563-71. PubMed ID: 8157970
[TBL] [Abstract][Full Text] [Related]
3. Early IL-4 production does not predict susceptibility to Leishmania major.
Scott P; Eaton A; Gause WC; di Zhou X; Hondowicz B
Exp Parasitol; 1996 Nov; 84(2):178-87. PubMed ID: 8932767
[TBL] [Abstract][Full Text] [Related]
4. Early infection with Leishmania major restrains pathogenic response to Leishmania amazonensis and parasite growth.
González-Lombana CZ; Santiago HC; Macedo JP; Seixas VA; Russo RC; Tafuri WL; Afonso LC; Vieira LQ
Acta Trop; 2008 Apr; 106(1):27-38. PubMed ID: 18313021
[TBL] [Abstract][Full Text] [Related]
5. TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis.
Liese J; Schleicher U; Bogdan C
Eur J Immunol; 2007 Dec; 37(12):3424-34. PubMed ID: 18034422
[TBL] [Abstract][Full Text] [Related]
6. Leishmania major: differential resistance to infection in C57BL/6 (high interferon-alpha/beta) and congenic B6.C-H-28c (low interferon-alpha/beta) mice.
Shankar AH; Morin P; Titus RG
Exp Parasitol; 1996 Nov; 84(2):136-43. PubMed ID: 8932763
[TBL] [Abstract][Full Text] [Related]
7. IL-4- and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains.
Noben-Trauth N; Paul WE; Sacks DL
J Immunol; 1999 May; 162(10):6132-40. PubMed ID: 10229856
[TBL] [Abstract][Full Text] [Related]
8. Mast cells are activated by Leishmania mexicana LPG and regulate the disease outcome depending on the genetic background of the host.
Villaseñor-Cardoso MI; Salaiza N; Delgado J; Gutiérrez-Kobeh L; Pérez-Torres A; Becker I
Parasite Immunol; 2008 Aug; 30(8):425-34. PubMed ID: 18507782
[TBL] [Abstract][Full Text] [Related]
9. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
[TBL] [Abstract][Full Text] [Related]
10. Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling.
Mohrs M; Ledermann B; Köhler G; Dorfmüller A; Gessner A; Brombacher F
J Immunol; 1999 Jun; 162(12):7302-8. PubMed ID: 10358179
[TBL] [Abstract][Full Text] [Related]
11. Immunological factors governing resistance and susceptibility of mice to Leishmania major infection.
Aguilar-Torrentera F; Carlier Y
Rev Latinoam Microbiol; 2001; 43(3):135-42. PubMed ID: 17061500
[TBL] [Abstract][Full Text] [Related]
12. LACK-reactive CD4+ T cells require autocrine IL-2 to mediate susceptibility to Leishmania major.
Gumy A; Aseffa A; Rachinel N; Breton M; Otten L; Tacchini-Cottier F; Röcken M; Doyen N; Acha-Orbea H; Locksley RM; MacDonald HR; Launois P; Louis J
Eur J Immunol; 2006 Jun; 36(6):1465-73. PubMed ID: 16637008
[TBL] [Abstract][Full Text] [Related]
13. CCL2-independent role of CCR2 in immune responses against Leishmania major.
Quinones MP; Estrada CA; Jimenez F; Martinez H; Willmon O; Kuziel WA; Ahuja SK; Ahuja SS
Parasite Immunol; 2007 Apr; 29(4):211-7. PubMed ID: 17371458
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological evaluation of anti-leishmanial activity by in vivo nitric oxide modulation in Balb/c mice infected with Leishmania major MRHO/IR/75/ER: an Iranian strain of cutaneous leishmaniasis.
Nahrevanian H; Farahmand M; Aghighi Z; Assmar M; Amirkhani A
Exp Parasitol; 2007 Jul; 116(3):233-40. PubMed ID: 17335813
[TBL] [Abstract][Full Text] [Related]
15. Leishmania major: recruitment of Gr-1+ cells into draining lymph nodes during infection is important for early IL-12 and IFN gamma production.
dos Santos MS; Vaz Cardoso LP; Nascimento GR; Lino Rde S; Dorta ML; de Oliveira MA; Ribeiro-Dias F
Exp Parasitol; 2008 Jul; 119(3):403-10. PubMed ID: 18501355
[TBL] [Abstract][Full Text] [Related]
16. Dissociation of disease susceptibility, inflammation and cytokine profile in lmr1/2 congenic mice infected with Leishmania major.
Elso C; Kumar B; Smyth G; Foote S; Handman E
Genes Immun; 2004 May; 5(3):188-96. PubMed ID: 14762398
[TBL] [Abstract][Full Text] [Related]
17. Leishmania amazonensis: participation of regulatory T and B cells in the in vitro priming (PIV) of CBA/J spleen cells susceptible response.
Veras PS; Welby-Borges M; de Santana CD; Nihei J; Cardillo F; de Freitas LA
Exp Parasitol; 2006 Jul; 113(3):201-5. PubMed ID: 16516200
[TBL] [Abstract][Full Text] [Related]
18. SCID mice reconstituted with IL-4-deficient lymphocytes, but not immunocompetent lymphocytes, are resistant to cutaneous leishmaniasis.
Satoskar A; Brombacher F; Dai WJ; McInnes I; Liew FY; Alexander J; Walker W
J Immunol; 1997 Nov; 159(10):5005-13. PubMed ID: 9366428
[TBL] [Abstract][Full Text] [Related]
19. Host genetic background determines whether IL-18 deficiency results in increased susceptibility or resistance to murine Leishmania major infection.
Wei XQ; Niedbala W; Xu D; Luo ZX; Pollock KG; Brewer JM
Immunol Lett; 2004 Jun; 94(1-2):35-7. PubMed ID: 15234532
[TBL] [Abstract][Full Text] [Related]
20. Leishmania major induces distinct neutrophil phenotypes in mice that are resistant or susceptible to infection.
Charmoy M; Megnekou R; Allenbach C; Zweifel C; Perez C; Monnat K; Breton M; Ronet C; Launois P; Tacchini-Cottier F
J Leukoc Biol; 2007 Aug; 82(2):288-99. PubMed ID: 17449725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
